These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 8379045

  • 1. [Risk for developing tumors in therapy with the proton pump inhibitor omeprazole].
    Eissele R, Arnold R.
    Versicherungsmedizin; 1993 Aug 01; 45(4):126-9. PubMed ID: 8379045
    [Abstract] [Full Text] [Related]

  • 2. [What are the indications for proton pump inhibitors? R. Arnold, Marburg, elaborates on the clinical aspects of the controversy regarding lansoprazole. Interview by Gerrit Lichtenberg].
    Arnold R.
    Fortschr Med; 1994 Jan 20; 112(1-2):44-5. PubMed ID: 8144120
    [No Abstract] [Full Text] [Related]

  • 3. Omeprazole.
    Med Lett Drugs Ther; 1990 Mar 09; 32(813):19-21. PubMed ID: 2179694
    [No Abstract] [Full Text] [Related]

  • 4. [Comment on the contribution: "Effect of omeprazole on serum gastrin levels: influence of age and sex" by Koop et al].
    Miederer SE.
    Z Gastroenterol; 1991 Apr 09; 29(4):177-8. PubMed ID: 1866976
    [No Abstract] [Full Text] [Related]

  • 5. Omeprazole: long-term safety.
    Arnold R, Koop H.
    Digestion; 1989 Apr 09; 44 Suppl 1():77-86. PubMed ID: 2691313
    [Abstract] [Full Text] [Related]

  • 6. Serum gastrin levels during long-term omeprazole treatment.
    Koop H, Klein M, Arnold R.
    Aliment Pharmacol Ther; 1990 Apr 09; 4(2):131-8. PubMed ID: 2104080
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical experience with omeprazole: assessment of efficacy and safety.
    Walan A.
    J Gastroenterol Hepatol; 1989 Apr 09; 4 Suppl 2():27-33. PubMed ID: 2491359
    [Abstract] [Full Text] [Related]

  • 11. [Omeprazole. A new substance for inhibiting acid production].
    Uhl D.
    Med Monatsschr Pharm; 1990 Feb 09; 13(2):34-7. PubMed ID: 2179691
    [No Abstract] [Full Text] [Related]

  • 12. Marked increase in gastric acid secretory capacity after omeprazole treatment.
    Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK.
    Gut; 1996 Nov 09; 39(5):649-53. PubMed ID: 9026477
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of omeprazole on serum gastrin levels: influence of age and sex.
    Koop H, Naumann-Koch C, Arnold R.
    Z Gastroenterol; 1990 Nov 09; 28(11):603-5. PubMed ID: 1981116
    [Abstract] [Full Text] [Related]

  • 16. Omeprazole, hypergastrinemia, and gastric carcinoid tumors.
    Freston JW.
    Ann Intern Med; 1994 Aug 01; 121(3):232-3. PubMed ID: 8017751
    [No Abstract] [Full Text] [Related]

  • 17. Effect of enprostil on serum gastrin and pepsinogen A and C levels in patients on long-term treatment with omeprazole.
    Meijer JL, Jansen JB, Biemond I, Kuijpers IJ, Lamers CB.
    Aliment Pharmacol Ther; 1994 Apr 01; 8(2):221-7. PubMed ID: 8038355
    [Abstract] [Full Text] [Related]

  • 18. [Therapeutic achlorhydria: for which diseases, when and for how long?].
    Koop H, Arnold R.
    Dtsch Med Wochenschr; 1988 Mar 31; 113(13):516-8. PubMed ID: 2894969
    [No Abstract] [Full Text] [Related]

  • 19. Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole.
    Hage E, Hendel L, Gustafsen J, Hendel J.
    Eur J Gastroenterol Hepatol; 2003 Jul 31; 15(7):781-9. PubMed ID: 12811309
    [Abstract] [Full Text] [Related]

  • 20. Omeprazole: a new drug for the treatment of acid-peptic diseases.
    Falk GW.
    Cleve Clin J Med; 1991 Jul 31; 58(5):418-27. PubMed ID: 1934456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.